<DOC>
	<DOCNO>NCT01287598</DOCNO>
	<brief_summary>- To evaluate effect BAY73-4506 pharmacokinetics probe substrates CYP 2C9 ( warfarin ) , 2C19 ( omeprazole ) 3A4 ( midazolam ) administer cocktail approach pharmacokinetics probe substrate CYP 2C8 ( rosiglitazone ) - To evaluate safety , anti-tumor activity , pharmacokinetics , pharmacodynamics BAY73-4506 patient advance solid tumor</brief_summary>
	<brief_title>BAY73-4506 Probe Substrate Study</brief_title>
	<detailed_description />
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Female male subject must ≥ 18 year first screen examination / visit ECOG Performance Status ≤ 2 Histological cytological documentation confirm advanced solid tumor . Subjects measurable nonmeasurable disease accord RECIST Life Expectancy least 3 month Adequate bone marrow , liver , renal function assess follow laboratory requirement conduct within 14 day prior first study treatment : Hemoglobin ≥ 9.0 g/dL Absolute neutrophil count ( ANC ) ≥1,500/mm3 Platelet count ≥ 100,000/ mm3 Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2 time ULN ALT AST ≤ 2.5 x ULN ( ≤ 5.0 x ULN subject cancer involve liver ) Serum creatinine ≤ 1.5 time ULN glomerular filtration rate ( GFR ) ≥ 30 ml/min/1.73 m2 , accord MDRD ( Modified Diet Renal Disease ) abbreviate formula Lipase ≤ 1.5 ULN INR PTT ≤ 1.5 ULN Subjects therapeutically treat warfarin , heparin anticoagulant eligible study participation Group A . Subjects therapeutically treat warfarin , heparin anticoagulant , allow participate Group B study provide meet eligibility criterion . Close monitoring least weekly evaluation perform INR PTT stable local standard care . Recovery previous drug/procedurerelated toxicity CTC Grade 0 1 level ( except alopecia ) , baseline precede prior treatment . Preexisting chemotherapy induce sensory neuropathy CTC Grade ≤2 exclusion criterion . Negative serum pregnancy test must obtain within 7 day prior start treatment woman childbearing potential . Negative result must available prior study treatment . Subjects enrol study must use adequate barrier birth control measure prior , course study , 3 month last administration regorafenib . An adequate contraception include use condom vasectomy , hormonal contraception implant combine PO contraceptive , certain intrauterine device , bilateral tubal ligation , hysterectomy . In addition , adequate birth control measure subject 's partner require , hormonal contraception implant combine PO contraceptive , certain intrauterine device , bilateral tubal ligation , hysterectomy , use condom vasectomy . History cardiac disease : Congestive heart failure ( New York Heart Association , NYHA , Class III IV ) active coronary artery disease ( unstable angina [ angina symptom rest ] newonset angina [ begin within last 3 month ] myocardial infarction within past 6 month ) . Treatment Type 1A 3 antiarrhythmic , Quinidine , Procainamide , Amiodarone , Sotalol permit . βBlockers digoxin permit . Left ventricular ejection fraction ( LVEF ) &lt; 50 % LLN institution ( whichever high ) . Subjects pheochromocytoma Dehydration NCICTCAE , version 4 , Grade &gt; 1 Uncontrolled hypertension ( failure diastolic blood pressure fall 90 mmHg systolic blood pressure fall 140 mmHg without use antihypertensive drug ) . At screen , subject history hypertension stable antihypertensive treatment least 7 day prior first dose study drug . Patients know allergy study drug ( ) administer , include know severe allergy , nonallergic drug reaction , multiple drug allergy study drug ( ) administer . This also include hypersensitivity compound excipients administer study subject , specifically regorafenib , warfarin , omeprazole midazolam subject Group A , rosiglitazone subject Group B . Subjects arterial venous thrombotic embolic event , cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis , pulmonary embolism within 6 month start study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Probe substrate</keyword>
	<keyword>target therapy</keyword>
	<keyword>small molecule</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>